7-3--dihydroxy-4--methoxyisoflavone and Heart-Failure

7-3--dihydroxy-4--methoxyisoflavone has been researched along with Heart-Failure* in 1 studies

Other Studies

1 other study(ies) available for 7-3--dihydroxy-4--methoxyisoflavone and Heart-Failure

ArticleYear
Bioinformatics and
    Frontiers in endocrinology, 2022, Volume: 13

    Heart failure (HF) and diabetes mellitus (DM) are life-threatening diseases. However, existing clinical drugs to treat HF complicated with DM are relatively limited. In this study, we performed a viable bioinformatics strategy combining network pharmacology and molecular docking to identify potential anti-HF and -DM targets and therapeutic mechanisms of calycosin, a functional phytoestrogen.. Web-based databases were used to collect candidate genes/targets of calycosin and HF/DM and then identify the hub bio-targets of calycosin against HF/DM. Using the online-available database, all functional processes and signaling pathways of calycosin against HF/DM were screened and identified before further visualization.. All potential bio-targets of calycosin and HF/DM were collected, and 20 hub targets of calycosin against HF/DM were identified. Interestingly, molecular docking findings indicated that mitogen-activated protein kinase-1 (MAPK1), β-arrestin 1 (ARRB1), and homologue-1 (ABL1) may be potent pharmacological targets of calycosin against HF/DM. In addition, all primary molecular functions of calycosin against HF/DM were identified, including regulating protein binding, ubiquitination, and the metabolic process. Furthermore, the top molecular pathways of calycosin against HF/DM were revealed, including cardiomyocyte and chemokine signaling pathways.

    Topics: Computational Biology; Diabetes Mellitus; Heart Failure; Humans; Isoflavones; Molecular Docking Simulation

2022